SeluDex Logo

International phase I/II expansion trial of the MEK inhibitor selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult Acute Lymphoblastic Leukaemia

Trial Overview and Summary

Key Details

Chief Investigator:

Dr Tobias Menne


University of Birmingham


Cancer Research UK, AstraZeneca & Imagine for Margo

Disease Site:

Acute Lymphoblastic Leukaemia (ALL)

Trial Type:

Clinical Trial Of an Investigational Medicinal Product





Open to New Sites?


Recruitment Start Date:

April 2018

Anticipated Recruitment End Date:

August 2022

CRCTU Trial Management Team:

Early Drug Development Team

Trial Email Address:


Trial Summary

This trial is to investigate the combination of selumetinib and dexamethasone in the treatment of relapsed/refractory acute lymphoblastic leukaemia (ALL) in both adults and children. The trial is specifically for patients who have an identified change (mutation) in a particular gene in their cancer’s DNA. Phase I is to find the most suitable dose of selumetinib to safely give with dexamethasone. Phase II will use this dose to find out how well the combination works.

Please note that the trials team cannot give individuals clinical advice. Patients who are interested in taking part in the trial and their families are advised to contact their health care professional to discuss if they may be eligible or refer to the CancerHelp website (see link below under More Information).

For Participating Sites

Please visit the For Investigators page which allow hospital sites participating in the SeluDex trial to access information and download current study documentation (password protected).

More Information